Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Archive for December, 2013

pSivida: Game On for Iluvien (PSDV, $4.29)

Alimera (ALIM) and pSivida (PSDV) released some extremely encouraging news on Iluvien. They said that Alimera had entered into labeling discussions with the FDA and as a result, both parties have agreed that there is no need for the previously scheduled January 2014, Dermatologic and Ophthalmic Advisory Committee meeting. A reasonable assumption is that the […]

A Trading Call on a Stock That I Like for the Long Term

I want to bring to the attention of paid subscribers to my website an idea that is essentially a trading idea on a stock on which I also have a very positive longer term view. I think that if my idea is correct that this stock could possibly have a 50% move and hopefully more, […]

Adam Feuerstein’s Views on Northwest Biotherapeutics (NWBO, $3.37)

Adam Feuerstein has consistently disagreed with authors who believe that there is a sound basis for Northwest Biotherapeutics (NWBO) conducting a phase III trial of DCVax-L in glioblastoma; I am one of those authors. I have never maintained that the trial will unquestionably succeed. I acknowledge that phase III trials conducted by both large and […]

Agenus: Encouraging Phase II Results for Prophage in Recurrent Glioblastoma (AGEN, $3.00)

Purpose of This Report Agenus issued a press release on December 16, 2013 in regard to the final results of a phase II trial of Prophage G-200 in recurrent glioblastoma based on an article in the journal Neuro-Oncology, the official journal of the Society of Neuro-Oncology. This was an open-label, single-arm, phase II study. Patients […]

ImmunoCellular: Post Hoc Analysis of Disappointing Phase II Trial of ICT-107 (IMUC, $1.02)

Investment Conclusion on ImmunoCellular The results of the phase II trial of ImmunoCellular’s (IMUC) ICT-107 were disappointing as they did not reach the specified endpoint of a 9.0 month improvement in median overall survival. The data suggests median overall survival of 2.0 months based on an intent to treat analysis of all 124 patients enrolled […]

Celldex: I View the Recent Data on Rindopepimut as Encouraging (CLDX, Hold, $22.52) (Subscribers Only)

Report Overview Celldex released interim data on the ReACT trial of rindopepimut in recurrent glioblastoma at the Society for Neuro-Oncology (SNO) on November 24, 2013. I am always cautious on rushing out with an interpretation of data from a clinical trial shortly after it is released. There are many different data points in a trial […]

Northwest Biotherapeutics: An Analysis of Its Transforming Balance Sheet Restructuring (NWBO, $4.14)

Key Takeaway Points of this Report Northwest (NWBO) restructured much of its debt in 4Q, 2012 and also has raised significant amounts of capital with four equity offerings over the last year that brought in $62 million. In part, because of the weak cash position, it had to issue warrants with each of these deals […]

Celldex: Equity Offering is a Positive for the Stock (CLDX, Hold, $25.88)

Celldex (CLDX) has just announced a financing in which the Company has issued 7.0 million shares and will receive net proceeds of $163 million. If the Green Shoe is exercised, as seems likely, shares issued and net proceeds would be 8.05 million and about $187 million, respectively. The Company had $136 million of cash as […]

What SmithOnStocks Is All About

Welcome to SmithOnStocks I want to welcome newsubscribers to my website. has been a process two years in the making and has taken me into the new world(for me)of the internet website. Designing the website and getting it functional has been much harder than I had envisioned and has taken much longer than expected. […]